Today: 25 January 2026
Subscribe
Browse Category

NYSE:NBY News 11 January 2026 - 12 January 2026

NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar

NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar

New York, January 12, 2026, 05:15 EST — Premarket NovaBay Pharmaceuticals, Inc. shares slipped roughly 10% in early Monday trading, falling to $17.21 after finishing Friday at $19.16. This dip comes after a notable surge in the lightly traded stock on the NYSE American. Stockanalysis Friday’s surge was extreme, even for a microcap. Shares closed up 102.5%, swinging between $9.69…
12 January 2026
·····
NovaBay stock more than doubles on thin float — what to watch for NBY when markets reopen

NovaBay stock more than doubles on thin float — what to watch for NBY when markets reopen

New York, January 11, 2026, 19:27 EST — Markets have closed for the day. Shares of NovaBay Pharmaceuticals, Inc. surged 102.54% to close Friday at $19.16, swinging between $9.69 and $19.95 during the session. Trading volume hit 9,996,659 shares. In after-hours trading, the stock reached $20.50. (StockAnalysis) U.S. markets were closed on Sunday, putting the spotlight on the NYSE American-listed…
12 January 2026
·····
NovaBay Pharmaceuticals stock jumps 102% — what to watch for NBY before Monday

NovaBay Pharmaceuticals stock jumps 102% — what to watch for NBY before Monday

New York, January 11, 2026, 07:38 EST — The market has closed. Shares of NovaBay Pharmaceuticals, Inc (NBY) soared Friday, closing up 102.5% at $19.16. The NYSE American stock will remain in focus when U.S. markets reopen Monday. (Daily Times Leader) Friday’s session ended a wild ride for the microcap, with shares bouncing between $9.69 and $19.95. Trading volume surged…
11 January 2026
·····

Stock Market Today

  • Neuland Laboratories Delivers 928% Share Price Surge Over Five Years Despite Recent Dip
    January 24, 2026, 9:33 PM EST. Neuland Laboratories (NSE:NEULANDLAB) saw its share price jump 928% in five years, outpacing its compound annual earnings per share (EPS) growth of 44%. The recent quarterly 18% decline and 3.8% drop year-to-date including dividends contrasts with a broader market rise of 4.7%. The company's total shareholder return (TSR), which factors dividends reinvested, hit 940%, reflecting strong dividend contributions. Investors appear optimistic, reflected in a price-to-earnings (P/E) ratio of 70.76, highlighting market expectations beyond current earnings growth. Analysts suggest examining Neuland's balance sheet and future fundamentals, as ongoing earnings growth and dividend policy will be key to sustaining shareholder value.
Go toTop